The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Apr. 19, 2011
Filed:
Jul. 24, 2003
Ellen M. Welch, Califon, NJ (US);
Neil Gregory Almstead, Princeton, NJ (US);
Robert F. Rando, Annandale, NJ (US);
Mathew C. Pellegrini, Bedminster, NJ (US);
Ellen M. Welch, Califon, NJ (US);
Neil Gregory Almstead, Princeton, NJ (US);
Robert F. Rando, Annandale, NJ (US);
Mathew C. Pellegrini, Bedminster, NJ (US);
PTC Therapeutics, Inc., South Plainfield, NJ (US);
Abstract
The present invention relates to a method for screening and identifying compounds that modulate premature translation termination and/or nonsense-mediated messenger ribonucleic acid ('mRNA') by interacting with a preselected target ribonucleic acid ('RNA'). In particular, the present invention relates to identifying compounds that bind to regions of the 28S ribosomal RNA (“rRNA”) and analogs thereof. Direct, noncompetitive binding assays are advantageously used to screen libraries of compounds for those that selectively bind to a preselected target RNA. Binding of target RNA molecules to a particular compound is detected using any physical method that measures the altered physical property of the target RNA bound to a compound. The structure of the compound attached to the labeled RNA is also determined. The methods used will depend, in part, on the nature of the library screened. The methods of the present invention provide a simple, sensitive assay for high-throughput screening of libraries of compounds to identify pharmaceutical leads.